FDA Grants Priority Review to Durvalumab in MIBC
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of patients with muscle-invasive bladder cancer in this curative-intent setting.
Related Articles
Pilot Program Improves Palliative Care Training for Hematology/Oncology Fellows
The director of the Hematology/Oncology Fellowship Training Program at Fox Chase Cancer Center discusses palliative care training for hematology/oncology fellows and highlights a pilot study…
Impact of thrombocytopenia on bleeding and thrombotic outcomes in adults with cancer-associated splanchnic vein thrombosis
Key PointsMajor bleeding and recurrent/progressive thrombosis were frequent complications in cancer-associated splanchnic vein thrombosis.Treatment with an
Fishing for 1q gain is now open in amyloidosis
In this issue of Blood, Chakraborty et al show that the presence of 1q gain in amyloid light chain (AL) amyloidosis is associated with a lower…
Novel Therapies and Combinations Augment Melanoma Treatment Arsenal
Omid Hamid, MD, discusses recent advances in the melanoma treatment landscape and highlights the 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.
First results of CAR-PRISM: early safety and efficacy of CAR-T in high-risk smoldering myeloma
Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the early safety and efficacy of CAR T-cell therapy in precursor myeloma, highlighting the promising results…
MRD Negativity & PFS Benefits in Transplant-Eligible NDMM : Oncology Times
An abstract is unavailable.
FDA Grants Priority Review to Durvalumab in MIBC
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of patients with muscle-invasive bladder cancer in this curative-intent…
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma
This randomized clinical trial evaluates the combination of veliparib and temozolomide in treating glioblastoma.
Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction
Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.
Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS
Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.